Cardiovascular genomics company CardioDX disclosed on Thursday that it raised $21 million in a planned $25 million round of new private funding.
The Palo Alto company led by CEO David Levison in April revived IPO plans that had stalled last fall, when it had hoped to raise up to $92 million, but it hasn't set a date for the offering nor updated its prospectus since.
Help employers find you! Check out all the jobs and post your resume.
